AlgoDynamix detects financial market anomalies that result in significant price disruptions. Our software identifies these anomalies and provides price changing analytics hours (or days) in advance of the disruption. The underlying risk analytics engine uses multi-source financial data feeds for detection and quantification. Customers include fund managers, wealth managers and other financial institutions with strong capital preservation mandates. The team have 30+ years of software development experience at top tier investment banks and consultancies including Goldman Sachs, McKinsey & Company and Bank of America Merrill Lynch.
Cytora uses web-based data to provide real time political risk assessments to organisations that operate in volatile, emerging or complex markets. Our customers are global companies who require up-to-date, highly localised risk information to make critical and data-driven decisions.
Cytora’s platform uses an event extraction system (based on natural language processing) to extract political risk events from web based data. It categorises events according to industry standard terminology, and delivers this data visually to customers in real time. We scrape 50,000 content sources a day, going through over one million articles a day, collecting over 30,000 risk events.
Better Origin (formerly Entomics)
Better Origin aims to convert food waste into energy. Our method uses insects – specifically the Black Soldier Fly – as an efficient biological catalyst for converting previous un-usable food waste into fat-rich larval biomass, which can then be refined into biodiesel. This process represents a sustainable alternative to existing biofuel production methods, which use ‘fuel crops’ that often replace arable food-producing land. In addition, our process yields a range of additional natural outputs ranging from compost to high-protein animal feed, which highlights the efficiency of the system and our company’s focus on sustainability.
Parkinson’s is a neurodegenerative disorder affecting 10 million people around the world. Despite the best available medical and surgical interventions people with Parkinson’s are often frustrated as they remain significantly limited in their activities. Charco Neurotech (formerly The Moment) developed CUE1, a focused vibrotactile stimulation device for people with Parkinson’s.
CUE1 uses a unique combination of two research-validated vibration-based Parkinson’s therapies; focussed stimulation and cueing. They help with initiation and execution of movement and reduce slowness to smoothen movement. The device also features a medication alert system, which the user can set in their phone. The device discretely reminds the user with a silent vibration when they need to take their medication. The CUE1 application also includes a number of fun games designed to track symptom severity over time. This data can be used by Parkinson’s specialists to help evaluate users during their checkups. All of the participants showed improved movement in our pilot testing by an average of 16%. Participants claimed they felt movement was smoother and better co-ordinated.
FLIT (formerly Hinton Bikes) is developing a new electric bike that is designed from the ground up to make it convenient for more people to cycle in our increasingly congested and polluted cities. It folds down small enough to take on a train, is light enough to carry upstairs, and is smart enough to tell you when to pump up your tyres. When you get home, simply drop it into its dock for charging. Our mission is to make riding a bike more convenient and reliable than driving a car so that we can get more people cycling in our cities.
Elpis BioMed aims to become a leading, global supplier of in vitro cell types for academic research and commercial drug discovery and development purposes. The cells could provide an alternative to the limited supply of primary cells and replace animal studies in other cases. Elpis Biomed’s proprietary technology allows it rapidly to generate highly mature, differentiated cell types at unmatched purity. The process is scalable with the potential to expand product offering with additional cell-types in the neuro-mesoderm focus area. Initial products will be cortical neurons, oligodendrocytes and skeletal muscle cells.
Healx is a social enterprise passionate about finding new therapeutic solutions to cure patients with rare diseases. We use advanced data analytics, such as machine learning and computational chemo-biology to identify novel drug applications in the area of rare diseases. Healx is fortunate to be supported by an extensive network of advisors from the Cambridge biomedical cluster, one of the leading biotech clusters in the world.
Our approach offers great promise both for patients suffering from rare diseases and for biopharmaceutical companies wishing to make the most of their therapeutic portfolio.
Immaterial have developed a porous material that can be put inside a gas tank to enable it to store 16 times as much gas at the same pressure and in the same volume. Hundreds of billions of pounds are spent every year on storing and transporting industrial gases. Our technology creates value by making this substantially more efficient, without impacting on current operational methods. We are able to unlock design flexibility and cost-savings in industries ranging from healthcare to industrial gas transport.
Kalium Health is developing the world’s first blood potassium test suitable for home use. The test will help chronic kidney patients and suffers of rare diseases to manage their health away from hospitals and clinics, improving health and lifestyles and significantly reducing the costs of healthcare provision. Our team combines world-class clinical, scientific and product development expertise.
KisanHub is a technology and data science start-up operating in the agriculture sector based in Cambridge, UK.
A cloud-based, integrated software platform, KisanHub brings together public and private data to help farmers take informed decisions about their day-to-day operations and markets. This data-driven decision-making platform will reduce input costs, boost returns, improve farm business efficiency and make farming more sustainable. KisanHub is the first decision support system to take an integrated approach towards data and curate disparate data sources to enable decision-making process.
LIFNanoRx is a nano-bio-med company focused on treatment of Multiple Sclerosis (MS), a disabling incurable auto-immune inflammatory disease of the central nervous system (CNS) commonly affecting young adults. LIF – short for Leukaemia Inhibitory Factor – is a critical stem cell factor that has unique biological properties: these not only promote tissue repair but also suppress disease-linked inflammation. These therapeutic properties are harnessed in LIFNanoRx’s targeted medicinal nanoparticle – “LIFNano” – providing a safe, cell-free, drug-free and potentially curative approach to MS. The technology is patented and LIFNanoRx holds worldwide exclusive licence in exploitation of LIF using their NanoMed platform technology.
Neutreeno provides a one-click software solution to e-commerce brands looking take immediate steps to decarbonise their processes. A carbon Stripe, Neutreeno’s platform integrates seamlessly to online webshops at the point of sale, allowing consumers to make their purchases carbon negative. Our software API evaluates the carbon intensity of the checkout cart and directs the micro-donations into a mixture of verified ecological projects & clean tech innovation ventures to drive the economy to net neutrality.
Nuclera Nucleics offers a path forward through our next generation DNA synthesis platform, which changes the paradigm on the creation of long DNA. Our technology enables efficient synthesis of longer DNA in a shorter amount of time compared to conventional synthesis. Our platform will make long DNA synthesis a readily available tool to meet the needs of any area of innovation, present or future.
Oh Lily! (formerly Water LilyPop)
We believe that eating is a necessity, but to eat intelligently is an art!
Oh Lily! is a range of sweet and savoury snacks made from water lily seeds. Water lily seeds have been used for centuries in traditional medicines such as Ayurveda and Chinese medicine for its high nutritional values. Still unknown in the western world, the potential of this plant is underutilised, and we aim to share the benefits of these seeds with our consumers, convinced that it will bring a snacking revolution. Indeed, more and more people are deciding to change their way of eating and choosing different diets. Health has become a priority, but the consumer doesn’t want to compromise on the taste, fun or texture. With its snacks, Oh Lily! is gathering all of those criteria to offer a healthy, tasty and crunchy experience. The seeds are naturally gluten-free and free from sugar and all our recipes are vegan, so Oh Lily! fits for all and is good for all.
In our project we aim to work closely with the local farmers and participate to the improvement of their livelihood, we would like to contribute to a more sustainable future for the food industry in term of product, packaging and supply chain.
Our mission is to take the consumer on a conscious culinary journey.
Outfield is providing farmers with access to new drone technologies. We are developing a range of innovative services using autonomous aircraft and computer vision systems. Outfield services range from land surveying to horticulture crop management, using systems that are faster, cheaper and more accurate than current field assessment techniques. Outfield is growing the future of precision farming.
PharmEnable explores new areas of chemical space that no one else is currently searching to enable the development of vital new medicines.
POCKiT diagnostic explores new areas of Stroke affects 16,000,000 people each year. 33% of patients will die and 90% of survivors will have a disability for the rest of their lives. POCKiT diagnostics have discovered a novel biomarker panel that could increase stroke patient treatment from 4% to 40%. We are leading a £1,000,000 grant from the United Kingdom government to finish an extensive clinical study in order to achieve regulatory approval. Our goal is to achieve market approval in 2020.
Qureight is a clinical data curation and analytics company which works in partnership with healthcare bodies and software developers in the field of artificial intelligence.
Through advanced infrastructure, coupled with technical and clinical expertise, the company performs annotation and analysis of anonymised data. Qureight exploits the value of data in their entirety and allows testing of machine learning algorithms, by collaborating with drug or technology companies, healthcare and academic institutions.
Qureight’s mission is to combine technology and life sciences to generate new knowledge and transform the way we use clinical data.
Satavia is an analytics and visualisation company that develops bespoke environmental awareness solutions for all segments of the aviation market. We aim to provide ‘personalised environmental health management’ for aircraft and unmanned aerial systems to reinforce the safety and reliability of flight operations, while minimising unanticipated maintenance costs. Satavia delivers live aircraft-centric metrics for a range of environmental threats and combines expertise in aeronautical meteorology, big data and analytics, and 3-D visualisation technology.
Simprints is a social enterprise committed to improving the lives of the poor. Accurately linking people to their digital records is a critical bottleneck in the delivery of mobile services in healthcare, microfinance, and aid distribution. We’re building a mobile biometric scanner and open-source software to empower the mobile tools used by researchers, NGOs and governments around the world.
Smartbell offers a simple precision agriculture solution for livestock rearing and management. The Smartbell system implements a fully-automated solution for livestock management, including distress alerts, herd analysis and customised farm management reports. Using advanced analytics on data gathered from animal wearables, Smartbell also cross references regional data to better understand resource utilisation and promote proven best practices.
Spirea, a spin-out from the University of Cambridge, is developing the next generation of antibody drug conjugate cancer therapeutics which carry more drug payload to tumour cells resulting in greater efficacy and tolerability and the ability to treat more cancer patients.
Spotta intends to be the world leader in smart pest detection. Our core technology is an ultra-low-power, insect monitoring sensor that can detect infestations early. By allowing earlier, cheaper intervention we aim to put a significant dent in the global $70 billion annual cost of invasive insect pests.
VocalIQ was a startup building technology for the next generation of spoken personal assistants. After several years of research at the University of Cambridge, the team spun out and joined the Accelerate programme in 2014. Following rapid growth to to 20 people, the company was sold to to Apple.